SecBot SecBot

NRSN

NeuroSense Therapeutics Ltd.
Nasdaq· Pharmaceutical Preparations· Inc. L3· CIK 0001875091 Biotech & Drug Discovery
$2.46 +0.02 (+0.82%)
Oct 23 4:00 PM ET · prev $2.44
Market cap
$4.6M
Nano cap
Consensus
Buy
89% Buy or better · 9 analysts
Median target
$52.00
+2014% · range $3.50–180.00
1 year
−89.2%
from $22.80 · Oct 27
30 days
−51.8%
from $5.10
52-week range
$2.39–24.80
−90% from high · low Oct 20
Avg volume 20D
28.1K
Oct 19 spike 117.6K
Short interest
26.9K
≈1.4% of shares · −29.7%
Days to cover
1.2
at average volume
Insider net
+$400.0K
2 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
8
analyzed by SecBot
SecBot read MIXED 4 reports · 90 days
Balance 1 bearish · 1 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 2/4
Strongest MIXED NeuroSense announced its Nasdaq hearing is scheduled for November 10, 2026, following a delisting…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    2 insiders bought $400.0K. No open-market sales.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 0 trimmed or exited.

  • AnalystsBULLISH

    8 of 9 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.800 → −$3.400 over 90 days.

  • Short sellersCOVERING

    Short interest −29.7% to 26.9K shares. 1.2 days to cover, ≈1.4% of shares.

  • TrendDOWNTREND

    59% below its 50-day average. New closing low $2.39 on Oct 20.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGDOUBLED108,636$78.2K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

9 analysts
Buy 89% rate it Buy or better
Strong Buy2Buy6Hold1Sell0Strong Sell0
12-month targets · 3 analysts

Price is below the lowest target. Median implies +2014%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Sep 28, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Sep 3, 2026HC Wainwright & Co.
INITIATE
INITIATEBuy
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 30, 2026
Trading halt
Halt Resumed: NRSN — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-09-30T13:46:45.000Z | Resumed 2026-09-30T13:51:45.000Z
Sep 30, 2026
Trading halt
Trading Halt: NRSN — LUDP (Volatility Trading Pause)
NeuroSense Thera Ltd Ord | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Sep 28, 2026
Press release
NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
Management will participate in the 5th Annual ROTH Healthcare Opportunities Conference on September 29, 2026 and will be available for one-on-one…
Sep 25, 2026
Press release
NeuroSense Provides Business Update and Progress for the First Half of 2026
CAMBRIDGE, Mass., Sept. 25, 2026 /PRNewswire/ -- Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical…
Sep 14, 2026
Trading halt
Halt Resumed: NRSN — trading resumed after T3 (News and Resumption Times)
Halted 2026-09-11T23:50:00.000Z | Resumed 2026-09-14T13:00:00.000Z

Insider ledger

Form 4
$400.0K
bought · 2 insiders
$0
sold · 0 insiders
DateInsiderTypeValue
Jun 16, 2026
Ben-Noon Alon
Chief Executive Officer
BUY$200.0K
Jun 16, 2026
Eisenberg Or
Chief Financial Officer
BUY$200.0K
Mar 26, 2026
Eisenberg Or
Chief Financial Officer
AWARD200,000 sh
Mar 26, 2026
Russek-Blum Niva
Chief Technology Officer
AWARD200,000 sh
Mar 26, 2026
Binder Hagit
General Manager
AWARD200,000 sh

Earnings setup

Estimates
−$3.40
EPS estimate, this quarter
−325%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$3.40-$3.40–-$3.40+0.0%$0.00
Next Q———$0.00
Current FY-$3.88-$4.45–-$3.30+49.7%$0.00
Next FY-$4.67-$7.12–-$2.23+65.4%$2.7M

Short side

FINRA· Sep 30, 2026
26,883
shares short
-29.7%
vs prior settlement
1.2
days to cover
≈1.4%
of shares outstanding
Trading halts
Sep 30, 2026Volatility PauseResumed
Sep 11, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 19, 2026 SEC
NeuroSense Therapeutics filed a U.S. patent application covering PrimeC (ciprofloxacin + celecoxib) for traumatic…
6-K — Impact 3/10
Oct 13, 2026 SEC
NeuroSense announced its Nasdaq hearing is scheduled for November 10, 2026, following a delisting determination for…
6-K — Impact 6/10
Sep 30, 2026 Trading halt
Halt Resumed: NRSN — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-09-30T13:46:45.000Z | Resumed 2026-09-30T13:51:45.000Z
Sep 25, 2026 SEC
NeuroSense Therapeutics reported H1 2026 financial results showing a net loss of $3.6 million (improved from $4.7…
6-K — Impact 7/10
Jun 30, 2026 Inst.
UBS Group AG — DOUBLED
108,636 shares ($78.2K)
Jun 16, 2026 Insider
Ben-Noon Alon bought 250,000 shares
Chief Executive Officer @ $0.8000 ($200.0K)
Jun 16, 2026 Insider
Eisenberg Or bought 250,000 shares
Chief Financial Officer @ $0.8000 ($200.0K)
Mar 26, 2026 Insider
Eisenberg Or was granted 200,000 shares
Chief Financial Officer

SecBot reports

8 filings · 3 bullish · 1 bearish · 2 mixed · 2 neutral
All NRSN filing & press-release reports (8)